ChemicalBook > CAS DataBase List > Acalabrutinib

Acalabrutinib

Acalabrutinib Structure
Acalabrutinib
  • CAS No.1420477-60-6
  • Chemical Name:Acalabrutinib
  • CBNumber:CB22756514
  • Molecular Formula:C26H23N7O2
  • Formula Weight:465.51
  • MOL File:1420477-60-6.mol
Acalabrutinib Property
  • Melting point >133°C (dec.)
  • Density 1.37±0.1 g/cm3(Predicted)
  • storage temp. Refrigerator
  • solubility Soluble in DMSO (up to at least 25 mg/ml)
  • pka 11.47±0.70(Predicted)
  • form solid
  • color Yellow
  • Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
  • InChIKey WDENQIQQYWYTPO-IBGZPJMESA-N
  • SMILES C(NC1=NC=CC=C1)(=O)C1=CC=C(C2=C3N(C([C@@H]4CCCN4C(=O)C#CC)=N2)C=CN=C3N)C=C1
  • NCI Dictionary of Cancer Terms acalabrutinib
  • FDA UNII I42748ELQW
  • NCI Drug Dictionary acalabrutinib
  • ATC code L01EL02
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H302-H315-H319-H335
  • Precautionary statements P261-P305+P351+P338

Acalabrutinib Chemical Properties,Usage,Production

  • Description Acalabrutinib (ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.
  • Uses Acalabrutinib, is an experimental anti-cancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL).
  • Definition ChEBI: Acalabrutinib is a member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a secondary carboxamide, a member of benzamides, a member of pyridines, an aromatic amine, a pyrrolidinecarboxamide, an imidazopyrazine, a ynone and a tertiary carboxamide.
  • General Description Class: non-receptor tyrosine kinase
    Treatment: CLL, SLL, MCL
    Oral bioavailability = 25%
    Elimination half-life = 0.9 h
    Protein binding = 97.5%
  • in vitro In the in vitro signaling assay on primary human CLL cells, acalabrutinib inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT. Acalabrutinib demonstrates higher selectivity for BTK with IC50 determinations on nine kinases with a cysteine residue in the same position as BTK. Importantly, unlike ibrutinib, acalabrutinib does not inhibit EGFR, ITK, or TEC. acalabrutinib has no effect on EGFR phosphorylation on tyrosine residues Y1068 and Y1173. Compared with ibrutinib, acalabrutinib has much higher IC50(>1000 nM) or virtually no inhibition on kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1.
  • in vivo Oral administration of ACP-196 in mice results in dose-dependent inhibition of anti-IgM-induced CD86 expression in CD19+ splenocytes with an ED50 of 0.34 mg/kg compared to 0.91 mg/kg for ibrutinib. A similar model is used to compare the duration of Btk inhibition after a single oral dose of 25 mg/kg. ACP-196 inhibits CD86 expression >90% at 3h postdose.
  • IC 50 3 nm
  • Metabolism Acalabrutinib has an absolute bioavailability of 25% and an elimination half-life of 0.9 h. Because of its better oral bioavailability but much shorter half-life than ibrutinib, acalabrutinib is taken at a lower dosage (100 mg) than ibrutinib (420 mg) but twice a day (vs. QD for ibrutinib). The major circulating metabolite in the plasma is the pyrrolidine ring-opened product 1. This metabolite also exhibited covalent BTK inhibition with potency 2-fold lower than acalabrutinib, and its kinase selectivity profile is similar to acalabrutinib. This active metabolite has a half-life of 6.9 h, much longer than the parent drug. However, the extent of its contribution to on-target covalent inhibition of BTK in humans remains to be established.
    Acalabrutinib
  • References 1) Wu et al.?(2016),?Acalabrutinib (ACP-196): a second-generation BTK inhibitor;?J. Hematol. Oncol.?9?21 2) Barf?et al.?(2017),?Acalabrutinib (ACP-196): A covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile;?J. Pharmacol. Exp. Ther.?363?240 3) Herman?et al.?(2017),?The Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia;?Clin. Cancer Res.?23?2831 4) Weber et al.?(2017),?Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity; Front. Immunol.?8?1454
Acalabrutinib Preparation Products And Raw materials
Raw materials
Preparation Products
Acalabrutinib Suppliers
Global(276)Suppliers
  • Supplier：
    Sinoway Industrial co., ltd.
  • Tel：0592-5800732;<br/>+8613806035118
  • Email：xie@china-sinoway.com
  • Country：China
  • ProdList：987
  • Advantage：58
  • Supplier：
    Capot Chemical Co.,Ltd.
  • Tel：+86-（0）57185586718<br/>+86-13336195806
  • Email：sales@capot.com
  • Country：China
  • ProdList：29730
  • Advantage：60
  • Supplier：
    Henan Tianfu Chemical Co.,Ltd.
  • Tel：+86-0371-55170693<br/>+86-19937530512
  • Email：info@tianfuchem.com
  • Country：China
  • ProdList：21628
  • Advantage：55

Related articles

Acalabrutinib Spectrum
1420477-60-6, AcalabrutinibRelated Search:
  • 抑制剂
  • 化学试剂
  • 药靶配体
  • 医药原料药API
  • 黄金产品
  • 普通产品
  • 杂质对照品
  • Acalabrutinib（阿卡替尼）
  • 原料药及中间体
  • 化工原料
  • 原料药
  • 医用原料
  • 原料药
  • 医用原料
  • 医药原料
  • 细胞生物学试剂
  • 第二代BTK抑制剂
  • 医药原料药
  • 阿可替尼,10 MM DMSO 溶液
  • 阿可替尼(阿卡替尼)
  • 阿卡替尼-[D4]/精确称量
  • 阿卡替尼相关杂质
  • 阿卡拉布替尼(ACP-196)
  • 阿卡拉布替尼
  • (S)-4-(8-氨基-3-(1-(丁-2-炔酰)吡咯烷-2-基)咪唑并[1,5-A]吡嗪-1-基)-N-(吡啶-2-基)苯甲酰胺
  • 阿卡拉替尼(ACP196)
  • 阿卡卢替尼
  • 艾克替尼
  • 阿卡拉替尼
  • (S)-4-(8-氨基-3-(1-(丁-2-炔酰基)吡咯烷-2-基)咪唑并[1,5-A]吡嗪-1-基)-N-(吡啶-2-基)苯甲酰胺
  • ACALABRUTINIB (ACP-196)阿卡替尼
  • ACP-196 抑制剂
  • 阿卡替尼 ACP-196
  • 阿可替尼(ACP-196)
  • (S)-4-[8-氨基-3-[1-(1-2-乙酰基)吡咯啉-2-酰基]咪唑[1,5-A]吡嗪-1-酰基]-N-(吡啶-2-酰基)
  • BTK抑制剂(ACALABRUTINIB)
  • 阿卡替尼
  • 4-[8-氨基-3-[(2S)-1-(1-氧代-2-丁炔-1-基)-2-吡咯烷基]咪唑并[1,5-A]吡嗪-1-基]-N-2-吡啶基-苯甲酰胺
  • 苯甲酰胺, 4-[8-氨基-3-[(2S)-1-(1-氧代-2-丁炔-1-基)-2-吡咯烷基]咪唑并[1,5-A]吡嗪-1-基]-N-2-吡啶基-
  • 阿可替尼
  • 1420477-60-6
  • Acalabrutinib, 10 mM in DMSO
  • 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
  • Calquence
  • ACP-196
  • ACP196
  • α-Dimethylglycine
  • α-Aminoisobutanoic acid
  • ACP196 1420477-60-6
  • BTK Inhibitor Pharma Raw Powder Acalabrutinib / ACP-196 For Treatment of Cancer
  • CS-1558
  • ACP-196; ACP196; ACP 196
  • EOS-60753
  • Acalabrutinib (ACP-196)
  • (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
  • 4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide
  • ACP196,Acalabrutinib
  • Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-

Home

My